Brief: JW (Cayman) Therapeutics Posts H1 Net Income RMB -240.3 Million
Aug 28 (Reuters) - JW (Cayman) Therapeutics H1 revenue RMB 86.8 million. * H1 net income RMB -240.3 million * H1 gross margin 50.4% * H1 gross profit RMB 43.7 million
Recent news on JW (Cayman) Therapeutics Co
See all newsChina pharma industry not impacted by Beijing scrutiny of sensitive tech deals, JW chief says
Brief: JW (Cayman) Therapeutics Appoints Tian Feng As CEO, Executive Director
Australia's Imugene gains on alliance with JW Therapeutics for tumour treatment
Brief: JW (Cayman) Therapeutics H1 Net Income RMB -267.3 Million
Brief: JW (Cayman) Therapeutics Grants Juno Therapeutics Non-Exclusive License